TOWA PHARMACEUTICAL (4553) FY2027 Q1 Earnings Report

Quick View

Executive Summary

The Company reported increases in both revenue and earnings for the quarter; however, the substantial increases in ordinary income and net income were largely attributable to the reversal of non-operating gains and losses. Revenue was ¥713.8B (+9.6% YoY), operating income was ¥65.2B (+25.2%), ordinary income was ¥79.4B (+100.9%), and net income attributable to owners of the parent was ¥55.3B (+120.1%). The operating margin improved to 9.1%, from 8.0% in the previous year, an improvement of +1.1pt, supported by a lower cost-of-sales ratio and restrained selling, general and administrative expense ratio. Meanwhile, the sharp increase in ordinary income was primarily driven by the reversal from a ¥14.5B loss on derivative valuation in the previous year to a ¥14.2B valuation gain in the current period, as well as the recognition of ¥3.4B in foreign exchange gains. The contribution from these temporary factors was substantial.

Factors Affecting Performance

【Revenue】Revenue increased to ¥713.8B, representing a +9.6% YoY increase. By segment, domestic revenue was ¥559.8B (78.4% of total, YoY +6.1%), while overseas revenue was ¥156.1B (21.6% of total, YoY +25.0%). Strong overseas growth drove the overall increase.

【Profitability】The gross profit margin improved to 36.6%, from 36.3% in the previous year, an improvement of +0.3pt. The SG&A expense ratio also declined by -0.9pt to 27.4%, from 28.3% in the previous year, resulting in an improvement in the operating margin to 9.1%, from 8.0%, an improvement of +1.1pt. Ordinary income surged to ¥79.4B (YoY +100.9%), primarily because non-operating derivative valuation gains and losses reversed from a ¥14.5B valuation loss in the previous year to a ¥14.2B valuation gain in the current period, together with the recognition of ¥3.4B in foreign exchange gains. The contribution from these temporary factors was substantial. Net income was ¥55.3B (YoY +120.1%), while the effective tax rate declined to 30.4%, from 36.5% in the previous year, contributing to the earnings increase. Operating income, ordinary income, and net income all increased; therefore, the overall conclusion is that the Company achieved higher revenue and higher earnings.

Segment Analysis

The domestic segment generated revenue of ¥559.8B (YoY +6.1%) and operating income of ¥70.1B (YoY +2.0%), with a 12.5% profit margin, making it the core earnings pillar that generates the majority of total Company profit. The overseas segment continued to achieve strong growth, with revenue of ¥156.1B (YoY +25.0%), but operating income remained at ¥0.05B, compared with a ¥5.6B loss in the previous year. Although the segment returned to profitability, its profit margin remained at virtually zero. Inter-segment adjustments totaled a negative ¥5.0B, primarily due to ¥5.1B in goodwill amortization, and were reflected in total Company operating income of ¥65.2B. The revenue mix remains weighted toward the domestic business, at 78.4% domestic and 21.6% overseas, indicating a high degree of dependence on the domestic business.

Key Financial Indicators

【Profitability】ROE was 3.0%, the operating margin was 9.1% (8.0% in the previous year), and the net profit margin was 7.7% (3.9% in the previous year), with all indicators improving from the previous year.【Cash Flow Quality】Operating Cash Flow (OCF) was limited to ¥7.3B, and the OCF-to-net-income ratio was approximately 0.13x, a low level relative to net income of ¥55.3B. Increases in inventories (-¥43.4B) and trade receivables (-¥9.1B) constrained cash generation.【Investment Efficiency】Capital expenditures were ¥30.9B, below depreciation and amortization expense of ¥45.5B, resulting in free cash flow of -¥25.7B.【Financial Soundness】The equity ratio was 38.0%, largely unchanged from 37.5% in the previous year, while the current ratio remained strong at 282.1%. At the same time, the Company continues to rely on debt-based financing, centered on long-term borrowings of ¥1,791.8B.

Cash Flow Analysis

OCF was ¥7.3B, down -87.6% from ¥58.9B in the previous year. Despite the increase in profit before tax, deterioration in working capital constrained cash generation. Specifically, the increase in inventories reduced OCF by ¥43.4B and the increase in trade receivables reduced OCF by ¥9.1B, while the ¥22.1B increase in trade payables provided a partial offset. Investing Cash Flow was -¥33.0B, of which capital expenditures accounted for ¥30.9B. Financing Cash Flow was -¥3.5B, as repayments of long-term borrowings (-¥63.5B) and increases in short-term borrowings (+¥16.3B), among other items, largely offset one another. As a result, free cash flow (OCF + investing cash flow) was -¥25.7B, indicating that investments and dividend payments during the quarter were financed through the use of cash on hand.

Earnings Quality

Operating income, which reflects recurring earnings capacity, increased +25.2% YoY to ¥65.2B, representing a substantive improvement supported by improvements in the gross profit margin and SG&A expense ratio. In contrast, the substantial increases in ordinary income and net income were largely driven by the reversal of market-sensitive items, namely the ¥14.2B gain on derivative valuation (compared with a ¥14.5B valuation loss in the previous year) and ¥3.4B in foreign exchange gains. From an earnings-quality perspective, some caution is therefore warranted regarding the sustainability of these gains. Extraordinary items were virtually nonexistent (extraordinary income of ¥0.0B and extraordinary loss of ¥0.0B), and the divergence between ordinary income and net income falls within the range explained by the 30.4% effective tax rate. Comprehensive income was ¥63.5B, exceeding net income of ¥55.3B by ¥8.2B. The primary factor was a +¥7.7B foreign currency translation adjustment, although the divergence between the two figures was limited.

Earnings Forecast and Guidance

Progress against the full-year plan was 23.5% for revenue, 20.4% for operating income, 26.5% for ordinary income, and 25.7% for net income. Compared with the benchmark of 25% for evenly distributed quarterly progress, operating income is slightly behind schedule, while ordinary income and net income are ahead. This difference reflects the aforementioned reversal in non-operating gains and losses, and progress at the operating level is somewhat conservative. The full-year plan calls for revenue of ¥3,040B (YoY +11.1%), operating income of ¥320B (YoY +38.5%), and ordinary income of ¥300B (YoY +6.8%), assuming an acceleration in earnings growth during the second half of the fiscal year. As of the current quarter, no revisions have been made to the earnings forecast or dividend forecast.

Shareholder Returns

The dividend forecast is ¥85.00 per share for common stock, implying a payout ratio of approximately 19.7% against forecast EPS of ¥430.77. No revision has been made to the dividend forecast as of the current quarter, and dividends paid during the period totaled ¥18.9B. No share repurchase has been disclosed. Since shareholder returns consist solely of dividends, they should be evaluated using the payout ratio rather than the total return ratio. In addition to common stock, the Company has issued a class of shares with different rights—Class A preferred shares—and the dividend terms for these shares are separately stipulated from those for common stock.

Risk Factors

1. Deterioration in working capital and weak cash conversion: OCF declined -87.6% YoY to ¥7.3B, and the ratio to net income of ¥55.3B remained at approximately 0.13x. Inventories increased by ¥43.4B and trade receivables increased by ¥9.1B, with longer inventory holding and collection periods constraining cash generation.

2. Profitability of the overseas segment: Overseas revenue grew strongly to ¥156.1B (YoY +25.0%), but operating income remained at ¥0.05B, leaving the profit margin at virtually zero. The gap with the domestic segment, which has a 12.5% profit margin, is substantial, and total Company earnings remain dependent on the domestic business.

3. Dependence on non-recurring non-operating gains and losses: The substantial increases in ordinary income and net income (YoY +100.9% and +120.1%, respectively) were largely driven by the reversal of market-sensitive items, namely the ¥14.2B derivative valuation gain and ¥3.4B foreign exchange gain. If these gains disappear in subsequent periods, the pace of earnings growth may slow.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

The operating margin is substantially below the industry median, while the net profit margin is slightly above the median, resulting in differing assessments within the industry at the operating and bottom-line levels.

Growth and Capital Efficiency

The revenue growth rate is approximately in line with the industry median, representing a standard pace of growth within the industry.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. The operating margin improved to 9.1%, from 8.0% in the previous year, confirming an improvement in profitability accompanied by improvements in both the gross profit margin and SG&A expense ratio.

2. The substantial increases in ordinary income and net income were primarily attributable to the reversal of non-operating derivative valuation gains and foreign exchange gains. The difference from the pace of core operating improvement (operating income YoY +25.2%) is an important consideration when assessing earnings quality.

3. The OCF-to-net-income ratio was a low 0.13x. The delay in cash generation caused by increases in inventories and trade receivables will be a key point to monitor in assessing progress in inventory turnover and capital efficiency for the full year.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly available data using a residual income model (Ohlson-type model with an explicit five-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥4,027–¥4,270 at cost of equity ±1%; ¥4,135–¥4,162 at ω±0.1.

Notes:

• Goodwill amortization of ¥41.4 per share is added back to earnings (to reflect a non-cash expense and enhance comparability with IFRS companies).
• Net assets as of the quarter-end are used (there is a timing difference relative to the full-year forecast).
• Since net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual income model / Interest rate reference month: 2026-07 / This value does not forecast or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.

---

AI Financial Analysis

Executive Summary

Towa Pharmaceutical delivered a strong FY2027 Q1 profit recovery, led by revenue growth, operating-margin expansion and a sharp improvement in overseas profitability. Revenue rose 9.6% year on year to ¥71.38bn. Operating income increased 25.2% to ¥6.52bn, materially outpacing sales growth. Ordinary income more than doubled to ¥7.94bn, while net income rose 120.1% to ¥5.53bn. Gross profit increased 10.2% to ¥26.10bn. The gross margin improved by approximately 22bp to 36.6%, indicating that pricing, product mix and/or manufacturing efficiency more than absorbed cost growth. SG&A expense grew 6.0%, below the 9.6% revenue increase, providing favorable operating leverage. The operating margin expanded by approximately 114bp to 9.1% from 8.0% in the previous-year quarter. Net margin improved by approximately 389bp to 7.8%, although the magnitude of the net-income increase was supported by non-operating items rather than operations alone. In particular, non-operating income rose to ¥2.28bn and non-operating expenses fell to ¥0.86bn from ¥2.02bn, with derivative valuation moving to a ¥1.42bn gain from a ¥1.45bn loss a year earlier. Domestic operations remained the core business, accounting for ¥55.98bn of revenue and ¥7.01bn of segment profit. Overseas revenue rose 24.5% to ¥15.40bn and the segment returned to a marginal profit of ¥0.01bn from a ¥0.56bn loss, a strategically positive turnaround despite still-low profitability. JGAAP goodwill amortization declined to ¥0.51bn from ¥1.11bn, which also helped reported operating-income growth. Cash conversion was the central weakness: operating cash flow was only ¥0.73bn against net income of ¥5.53bn, and free cash flow was negative ¥2.57bn. Working-capital absorption, especially inventory expansion, income-tax payments and derivative-related cash-flow effects, constrained cash generation. Liquidity is ample, with a 282.1% current ratio and ¥42.23bn of cash, but the balance sheet remains meaningfully leveraged, with ¥187.94bn of interest-bearing debt and reported Debt/EBITDA of 17.0x. Full-year guidance was maintained, and Q1 operating-income progress of 20.4% is below the standard 25% quarterly run rate, whereas net-income progress of 25.7% is slightly ahead. The investment debate therefore centers on whether the operational improvement and overseas turnaround can continue while cash conversion, inventory discipline and debt reduction improve.

Profitability Analysis

Annualized ROE was 12.1%, which is within the 10-15% range generally regarded as good, but it is supported by a relatively high 2.63x financial-leverage factor. The DuPont decomposition is annualized net profit margin of 7.8%, asset turnover of 0.594x and financial leverage of 2.63x. Margin improvement was the principal positive driver of profitability: gross margin rose to 36.6% and operating margin rose to 9.1%. The improvement in operating profit was supported by revenue growth exceeding SG&A growth, with SG&A up 6.0% versus sales growth of 9.6%. Domestic segment profit grew only 2.0% to ¥7.01bn despite domestic revenue growth of 6.1%, implying a domestic segment-margin decline of roughly 55bp to 12.5%. Conversely, the overseas segment's movement to breakeven from a ¥0.56bn loss was the most significant segment-level profitability change. Consolidated operating-income growth also benefited from lower JGAAP goodwill amortization, which fell by ¥0.60bn year on year to ¥0.51bn. Goodwill amortization represented 4.4% of EBITDA before goodwill amortization of ¥11.58bn, indicating a modest rather than material JGAAP-versus-IFRS earnings distortion. Ordinary income grew faster than operating income because non-operating income increased and non-operating expenses declined substantially. The derivative valuation swing was a meaningful contributor to the increase in pre-tax and net income, so the 120.1% net-income growth rate should not be extrapolated as fully recurring. The effective tax rate was 30.4%, producing a tax burden of 0.696, close to a normal corporate tax outcome. The interest burden of 1.218x exceeded 1.0x because pre-tax profit benefited from net non-operating gains; it should not be interpreted as an absence of financing cost, given ¥0.63bn of quarterly interest expense. Interest coverage remained adequate at 10.38x on an EBIT basis and 17.63x on an EBITDA basis. Annualized ROA, calculated using Q1 net income annualized against average assets, was approximately 4.6%, indicating returns remain more moderate on the asset base than the ROE headline suggests.

Growth Assessment

Revenue growth of 9.6% was broad-based across the reported geographic segments. Domestic revenue increased 6.1% to ¥55.98bn, demonstrating continued expansion in the company's principal market. Overseas revenue increased 24.5% to ¥15.40bn, lifting the overseas revenue share to 21.6% from 19.0% a year earlier. The overseas business returned to a small segment profit, which improves the quality of international growth relative to a loss-making expansion model. However, overseas segment margin was close to zero, so sustained earnings contribution requires further scale benefits and/or cost normalization. Gross-margin expansion supports the view that top-line growth was not purchased solely through margin sacrifice. Operating leverage was favorable because SG&A grew more slowly than sales. Full-year sales guidance is ¥304.0bn, implying Q1 progress of 23.5%, 1.5 percentage points below the standard 25% pace. Full-year operating-income guidance is ¥32.0bn, and Q1 progress is 20.4%, 4.6 percentage points below the standard pace. Full-year ordinary-income guidance is ¥30.0bn, and Q1 progress is 26.5%, slightly ahead of the standard quarterly pace. Full-year net-income guidance is ¥21.5bn, with Q1 progress at 25.7%, also modestly ahead of the standard pace. The divergence between operating-income and net-income progress indicates that non-operating gains are currently contributing more than the underlying operating run rate. The absence of forecast revisions leaves management's FY2027 operating-income target intact, but subsequent quarters need to demonstrate further domestic margin recovery and sustainable overseas profitability.

Financial Health

Liquidity is strong. Current assets of ¥275.76bn exceed current liabilities of ¥97.75bn, resulting in working capital of ¥178.01bn and a current ratio of 282.1%. The quick ratio of 224.9% confirms that liquidity is not dependent on selling inventory. Cash and deposits of ¥42.23bn cover short-term loans of ¥8.77bn by 4.82x. Short-term debt represents only 4.7% of interest-bearing debt, limiting immediate refinancing pressure. Accordingly, there is no evident short-term maturity mismatch between current assets and short-term funding obligations. Solvency is more constrained than liquidity: interest-bearing debt totals ¥187.94bn, including ¥179.18bn of long-term loans. Debt-to-equity is 1.63x, below the 2.0x aggressive-leverage warning threshold but elevated for a company with volatile operating cash conversion. Debt/capital is 50.7%, indicating debt remains a major component of the capital structure. The reported Debt/EBITDA ratio of 17.0x is a material high-leverage warning and is substantially above the 4.0x high-yield benchmark. This metric is particularly relevant because it indicates a long deleveraging period if measured against the reported quarterly EBITDA base. Interest coverage remains a mitigating factor, at 10.38x on EBIT and 17.63x on EBITDA. Equity increased to ¥182.48bn from ¥178.10bn, supported by quarterly comprehensive income of ¥6.35bn. Goodwill is limited at 4.9% of equity and 1.9% of assets, while total intangible assets are 5.4% of assets, so the balance sheet is not heavily dependent on M&A asset values. Lease obligations total ¥19.36bn, and sale-and-leaseback proceeds of ¥3.74bn during the quarter indicate that lease financing is part of the funding mix.

Cash Flow Quality

Cash-flow quality is weak in FY2027 Q1 despite strong reported earnings. Operating cash flow was ¥0.73bn, equivalent to only 0.13x net income of ¥5.53bn, well below the 0.8x quality threshold. Cash conversion, measured as operating cash flow divided by EBITDA, was only 0.07x, versus a level above 0.7x generally viewed as healthier. Free cash flow was negative ¥2.57bn after capital expenditure of ¥3.09bn. Inventory increased by ¥4.34bn, representing a major use of operating cash and a key explanation for the divergence between profit and cash generation. Trade receivables increased by ¥0.91bn, adding further working-capital pressure. Trade payables increased by ¥2.21bn, partly offsetting these cash outflows but not fully financing the inventory build. Income taxes paid were ¥4.09bn, materially reducing reported operating cash flow. The cash-flow statement also includes a ¥1.42bn derivative valuation gain adjustment, highlighting that part of the accounting profit uplift was non-cash at the quarter end. The 1.0% accruals ratio is low and does not independently signal broad accrual-accounting stress, but the cash shortfall is nevertheless material and needs monitoring. The reported DSO alert of 83 days is above the 60-day warning threshold and raises collection-efficiency risk. Inventory-day alerts range from 113 to 258 days depending on the methodology used; both reported measures are elevated relative to their respective 60-day and 90-day warning thresholds. The reported 293-day cash conversion cycle is also substantially above the 120-day warning benchmark. These working-capital indicators are especially important for a generic-pharmaceutical manufacturer, where inventory availability is important but excess stocks can create obsolescence, pricing and write-down risk. CapEx/depreciation was 0.68x, just below the 0.7x underinvestment threshold. While quarterly timing can affect this ratio, continued capital expenditure below depreciation could eventually constrain manufacturing renewal, capacity upgrades and quality-system investment.

Dividend Sustainability

The full-year common-share dividend forecast is ¥85.00 per share. Against forecast EPS of ¥430.77, the implied dividend payout ratio is approximately 19.7%, which is conservative and well below the 60% sustainability benchmark. The forecast dividend therefore appears covered by forecast accounting earnings. However, Q1 free cash flow was negative ¥2.57bn, and operating cash flow of ¥0.73bn did not cover capital expenditure of ¥3.09bn. Cash dividends paid during the quarter were ¥1.89bn, exceeding Q1 operating cash flow. Dividend sustainability consequently depends less on the stated earnings payout ratio and more on normalization of operating cash generation in the remaining quarters. The company has substantial liquidity and no immediate short-term debt funding pressure, which provides near-term payment capacity. Nevertheless, reported leverage is high on the Debt/EBITDA metric, so retaining cash for deleveraging and working-capital management remains financially important. No common-share dividend revision has been announced.

Risk Assessment

Business risks include Domestic segment margin declined by roughly 55bp despite 6.1% revenue growth, creating risk that sales growth does not translate proportionately into domestic profit., Overseas revenue rose 24.5%, but segment profit was only ¥0.01bn; the turnaround remains fragile and exposed to pricing, distribution, currency and execution risks., For a generic-pharmaceutical producer, reimbursement-price revisions, generic competition, procurement-cost inflation and pressure to maintain reliable supply can limit margin expansion., Elevated inventory days and a 293-day reported cash conversion cycle raise risk of inventory obsolescence, slower-moving products and future valuation losses., Derivative valuation gains contributed to non-operating profit growth; reversal of market or currency conditions could reduce ordinary income..

Financial risks include Reported Debt/EBITDA of 17.0x is a high-leverage alert and indicates limited flexibility if EBITDA or cash flow weakens., Operating cash flow of ¥0.73bn was only 13% of net income, exposing the company to a need for balance-sheet liquidity or external funding if working-capital absorption persists., Free cash flow was negative ¥2.57bn after ¥3.09bn of capital expenditure., Long-term loans of ¥179.18bn account for most interest-bearing debt, leaving future earnings exposed to refinancing conditions and interest-rate movements., Sale-and-leaseback funding and ¥19.36bn of lease obligations add fixed financial commitments alongside borrowings..

Key concerns include EARNINGS_QUALITY alert: OCF/net income of 0.13x reflects a large divergence between accounting earnings and cash earnings, driven by inventory growth, receivable growth, taxes and derivative-related cash-flow adjustments., LOW_CASH_CONVERSION alert: OCF/EBITDA of 0.07x indicates that current EBITDA is not converting into cash at an acceptable rate., UNDERINVESTMENT and CAPEX_UNDERINVESTMENT alerts: CapEx/depreciation of 0.68x is below 0.7x; persistence could defer manufacturing, compliance or capacity investment needs., HIGH_LEVERAGE and REIT_FINANCIAL_RISK alerts: reported Debt/EBITDA of 17.0x materially exceeds both 4.0x and 8.0x warning levels. Although the company is not a REIT, the leverage signal remains relevant to credit risk., HIGH_RECEIVABLE_DAYS alert: reported DSO of 83 days exceeds 60 days, requiring attention to collection discipline and customer payment patterns., HIGH_INVENTORY_DAYS alerts: reported inventory-day measures of 113 and 258 days are each elevated under their respective methodologies and reinforce the risk of inefficient working-capital deployment., LONG_CCC alert: the reported 293-day cash conversion cycle is materially above 120 days and is inconsistent with the level of cash conversion expected from the reported earnings recovery..

Investment Implications

Key takeaways include Revenue growth, gross-margin expansion and SG&A discipline produced a 25.2% increase in operating income., The overseas segment moved from loss to breakeven as revenue increased 24.5%, but it has not yet become a meaningful earnings contributor., Net-income growth materially exceeded operating-income growth because of lower non-operating expenses and derivative valuation gains., Liquidity is strong, but high reported Debt/EBITDA and weak free-cash-flow generation make deleveraging and working-capital execution central issues., Goodwill and intangible-asset exposure is modest, limiting M&A-related impairment risk relative to equity and assets., The ¥85 common-share dividend forecast implies a conservative 19.7% payout ratio on forecast EPS, although quarterly cash coverage was weak..

Metrics to watch include Domestic segment profit margin and the durability of gross-margin expansion, Overseas segment profitability following its return to breakeven, Operating cash flow relative to net income and EBITDA, Inventory balances, reported inventory days and the cash conversion cycle, Receivables collection period and DSO, Debt/EBITDA, net debt trend, long-term loan repayments and interest expense, Capital expenditure relative to depreciation and manufacturing-investment requirements, Progress toward FY2027 guidance: sales ¥304.0bn, operating income ¥32.0bn, ordinary income ¥30.0bn and net income ¥21.5bn.

Regarding relative positioning, The company shows good annualized ROE of 12.1%, a solid 9.1% operating margin and robust liquidity, but its profile is less favorable on cash conversion and reported leverage. For a generic-pharmaceutical manufacturer, the combination of improving operating profitability and a still-extended working-capital cycle makes the sustainability of cash earnings more important than the headline Q1 net-income growth rate.